There is growing interest in RNA-based biomarkers and measuring RNA expression holds great promise for stratifying patients based on drug response, drug efficacy and risk of side effects. RNAscope in situ hybridization enables molecular detection in a morphological context. It provides the cellular resolution required to evaluate tissue heterogeneity and to potentially better screen and select patients.
The use of RNAscope ISH as a companion diagnostic (CDx) has been critical to the increasing clinical success of certain drugs. With this in mind, ACD developed a CDx Feasibility and Prototype Biomarker Assay Development program. The Professional Assay Services team of scientists, pathologists, and technical experts has a decade of experience in developing assays for clinical applications and enabling companion diagnostic development. The established workflow includes assay development and optimization followed by demonstration of specificity and sensitivity, stability, robustness, repeatability and intermediate precision, and other validation parameters.
Validation Parameters for Assay Prototype Development
Assay transfer: Our scientists produce a detailed technical report describing the assay conditions optimized for the tissues of interest. Our Field Application Specialist will work closely with your team to ensure successful training of the protocol and enable a faster transfer into your lab or external lab of your choice.
Assay Services by CLIA-Certified Providers
For Phase II clinical trials and beyond, our CLIA-Certified RNAscope™ Service Provider program is designed to support clinical trials for Advanced Cell Diagnostics’ leading pharmaceutical clients.
